Amyloid Cascade Pathway

Amyloid Cascade Pathway

Overview

Amyloid Cascade Hypothesis describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.

Amyloid Cascade Hypothesis represents the dominant and most influential theoretical framework in Alzheimer's disease (AD) research, proposing that the accumulation of amyloid-beta (Aβ) peptides serves as the primary pathogenic trigger leading to downstream pathological events including tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, neuronal death, and progressive cognitive decline[@hardy1992][@selkoe2016]. First articulated in its modern form in 1992 by John Hardy and Gerald Higgins at the National Institute on Aging, this hypothesis has profoundly shaped Alzheimer's disease research, therapeutic development strategies, and clinical trial design over the past three decades. The hypothesis catalyzed billions of dollars in research investment and fundamentally transformed how scientists conceptualize disease mechanisms in neurodegenerative disorders. Despite significant challenges and revisions over the years, core elements of the hypothesis continue to guide contemporary therapeutic approaches.

Historical Development and Evolution

Origins and Initial Formulation (1992)

Amyloid Cascade Pathway

Overview

Amyloid Cascade Hypothesis describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.

Amyloid Cascade Hypothesis represents the dominant and most influential theoretical framework in Alzheimer's disease (AD) research, proposing that the accumulation of amyloid-beta (Aβ) peptides serves as the primary pathogenic trigger leading to downstream pathological events including tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, neuronal death, and progressive cognitive decline[@hardy1992][@selkoe2016]. First articulated in its modern form in 1992 by John Hardy and Gerald Higgins at the National Institute on Aging, this hypothesis has profoundly shaped Alzheimer's disease research, therapeutic development strategies, and clinical trial design over the past three decades. The hypothesis catalyzed billions of dollars in research investment and fundamentally transformed how scientists conceptualize disease mechanisms in neurodegenerative disorders. Despite significant challenges and revisions over the years, core elements of the hypothesis continue to guide contemporary therapeutic approaches.

Historical Development and Evolution

Origins and Initial Formulation (1992)

The Amyloid Cascade Hypothesis emerged from converging observations in the early 1990s. The identification of pathogenic mutations in the Amyloid Precursor Protein (APP) gene located on chromosome 21 in families with autosomal dominant Alzheimer's disease provided the genetic foundation[@hardy1992]. Additionally, neuropathological studies demonstrating amyloid plaques as a defining feature of AD pathology, combined with biochemical characterization of Aβ as a proteolytic cleavage product of APP, led to the formulation that Aβ accumulation initiates a cascade of downstream events. Hardy and Higgins proposed that Aβ deposition leads to neurofibrillary tangle formation through as-yet-undefined mechanisms, culminating in neuronal loss and clinical dementia. This model offered a testable hypothesis that connected genetic findings to disease pathology and provided a logical framework for therapeutic intervention.

Major Revisions and Refinements (1995-2010)

Subsequent decades witnessed significant refinements to the original hypothesis as new experimental evidence accumulated[@walsh2005]. Researchers identified soluble Aβ oligomers as the most toxic species, shifting focus from insoluble fibrils (plaques) to soluble oligomers as the primary neurotoxic entities. This "oligomer hypothesis" emerged from studies demonstrating that soluble Aβ assemblies correlate more strongly with cognitive impairment than plaque burden. The concept of "oligomeric synaptic dysfunction" developed, suggesting that soluble Aβ assemblies preferentially target synapses, leading to memory impairment even before overt plaque formation. Furthermore, the hypothesis expanded to incorporate evidence that Aβ accumulation occurs decades before clinical symptoms, establishing the critical framework for preventive therapeutic interventions in asymptomatic individuals.

Contemporary Interpretations (2010-Present)

Modern iterations of the hypothesis acknowledge significant complexity that was not appreciated in earlier formulations[@price2004]. The relationship between Aβ and tau pathology appears bidirectional rather than strictly sequential, with evidence of synergistic toxicity between these two protein aggregates. The persistence of cognitive decline in clinical trials despite successful plaque removal has prompted fundamental reconsideration of Aβ as the sole driver of neurodegeneration. Current models emphasize multiple contributing factors including age-related cellular vulnerabilities, chronic neuroinflammation, metabolic disturbances, vascular dysfunction, and lipid processing abnormalities that interact with Aβ to determine disease progression. This evolution from a linear model to a network model represents the mature understanding of AD pathogenesis.

Molecular Biology of Amyloid-Beta Production and Metabolism

Amyloid Precursor Protein (APP) Structure and Function

APP is a type I transmembrane protein belonging to the APP family, which also includes APLP1 and APLP2. Expressing at high levels throughout the body, APP is particularly abundant in neuronal synapses where it participates in synaptic formation, plasticity, and repair. The protein comprises a large extracellular domain, a single transmembrane region, and a short cytoplasmic tail that interacts with numerous signaling proteins.

The full-length APP molecule undergoes proteolytic processing through two major mutually exclusive pathways with profoundly different consequences for Aβ generation[@selkoe2016]. The non-amyloidogenic pathway, which predominates under physiological conditions, involves cleavage by α-secretase within the Aβ sequence, thereby preventing Aβ formation entirely. This cleavage generates soluble APPα (sAPPα), a fragment possessing neurotrophic and neuroprotective properties, and a membrane-bound C-terminal fragment (C83) subsequently processed by γ-secretase. The amyloidogenic pathway initiates with β-secretase (BACE1) cleavage at the N-terminus of Aβ, producing soluble APPβ (sAPPβ) and the C-terminal fragment C99. The γ-secretase complex then processes C99 to generate Aβ peptides of varying lengths.

BACE1: The Beta-Secretase

BACE1 (Beta-site APP Cleaving Enzyme 1) represents the rate-limiting enzyme in amyloidogenic APP processing[@egan2018]. As an aspartyl protease, BACE1 requires optimal pH conditions and undergoes complex trafficking through the secretory pathway. The enzyme achieves high activity in endosomes, where the acidic environment promotes optimal catalytic function. BACE1 expression is developmentally regulated, with highest expression in the brain during early development. Genetic knockout of BACE1 completely abolishes Aβ production in mice, establishing BACE1 as the sole β-secretase. However, BACE1 deficiency in adult mice produces unexpected cognitive and synaptic deficits, raising concerns about therapeutic targeting.

γ-Secretase and the Generation of Aβ Peptide Heterogeneity

The γ-secretase complex comprises four essential components: Presenilin 1 or Presenilin 2 (the catalytic aspartyl proteases), Nicastrin, APH-1 (Anterior Pharynx Defect 1), and PEN-2 (Presenilin Enhancer 2)[@selkoe2016]. This unusual aspartyl protease complicated functions as an intramembrane cleaving enzyme (I-CLiP), executing proteolysis within the lipid bilayer. γ-Secretase performs processive cleavage along the transmembrane domain, releasing Aβ peptides of varying lengths. The precise cleavage positions determine the physicochemical properties and biological activities of the resulting Aβ species. The Aβ42/Aβ40 ratio is increased in familial AD cases with PSEN1/PSEN2 mutations, explaining the enhanced pathogenicity of these genetic variants.

Aβ Peptide Species and Their Properties

The γ-secretase cleavage produces a heterogeneous mixture of Aβ peptides with different aggregation propensities and biological activities[@selkoe2016]. Understanding the relative abundances and toxicity profiles of these species is critical for therapeutic development.

| Species | Relative Prevalence | Aggregation Tendency | Neurotoxicity | Clinical Relevance |
|---------|-------------------|---------------------|---------------|-------------------|
| Aβ37 | ~15-20% | Very Low | Minimal | Associated with CAA |
| Aβ38 | ~10-15% | Low | Lower | Vascular pathology |
| Aβ40 | ~80-90% | Moderate | Lower | Most abundant |
| Aβ42 | ~5-10% | High | Higher | Plaque core component |
| Aβ43 | Trace | Very High | Highest | Early seed |

Aβ42 and Aβ43 exhibit greater hydrophobicity and enhanced tendency to form oligomers and fibrils, explaining their stronger association with pathological deposition[@selkoe2016]. The longer species initiate aggregation at lower concentrations and propagate more rapidly. Evidence suggests Aβ43 can template conversion of Aβ40 and Aβ40 into neurotoxic oligomers, establishing a prion-like propagation mechanism.

Clearance Mechanisms and Their Dysregulation

Enzymatic Degradation

Multiple proteolytic enzymes contribute to Aβ catabolism under physiological conditions[@salloway2022]. Neprilysin (NEP) emerges as the most important Aβ-degrading enzyme in the brain, functioning at the cell surface and in intracellular compartments. Neprilysin expression decreases with aging, potentially contributing to age-related Aβ accumulation. Insulin-degrading enzyme (IDE) also degrades Aβ, with particular importance in intracellular clearance. Matrix metalloproteinases (MMPs), particularly MMP-9, contribute to extracellular Aβ degradation. Genetic manipulated studies demonstrate that neprilysin overexpression reduces Aβ burden and improves cognitive function in transgenic mice.

Cellular Clearance Pathways

Microglial phagocytosis represents a critical cellular clearance mechanism for Aβ. These brain-resident immune cells recognize Aβ through pattern recognition receptors, including Toll-like receptors (TLRs) and the scavenger receptor CD36. Microglial activation can be protective in early disease stages, promoting Aβ clearance. However, chronic microglial activation leads to inflammatory cytokine release that may exacerbate neurodegeneration. Astrocytes also participate in Aβ clearance through receptor-mediated uptake and lysosomal degradation. The balance between productive clearance and harmful inflammation determines whether microglial responses are beneficial or detrimental.

Perivascular and Drainage Pathways

The brain possesses dedicated perivascular drainage pathways that remove Aβ from the interstitial fluid[@sims2023]. The glymphatic system, a recently characterized waste clearance system, facilitates convective transport of solutes along perivascular spaces. Arterial pulsation drives bulk flow, with Aβ along this pathway. The functionality of glymphatic clearance decreases with aging, potentially contributing to protein accumulation. Sleep disruption reduces glymphatic function, providing a mechanistic link between sleep disturbances and AD risk. Vascular dysfunction, including reduced peristalsis and endothelial injury, impairs clearance and promotes Aβ deposition in cerebral vessels (Cerebral Amyloid Angiopathy).

Blood-Brain Barrier Transport

The blood-brain barrier (BBB) controls Aβ exchange between the brain and systemic circulation. Receptor-mediated transport systems mediate brain-to-blood Aβ export, with LRP1 (Low-density lipoprotein receptor-related protein 1) playing a major role. RAGE (Receptor for Advanced Glycation End-products) mediates peripheral-to-brain Aβ transport, potentially contributing to brain accumulation from blood sources. ABC transporters (particularly P-glycoprotein) participate in efflux. Competition between these transport systems determines net Aβ flux. Dysfunction of BBB transport systems in aging and AD impairs clearance and contributes to accumulation.

Genetic Architecture of Alzheimer's Disease

Autosomal Dominant Alzheimer's Disease (ADAD)

Mutations causing early-onset familial AD provide the most compelling genetic support for the amyloid hypothesis[@hardy1992][@dunn2024]. These highly penetrant variants follow Mendelian inheritance patterns and cause disease onset typically before age 60. Over 300 pathogenic mutations have been identified in APP, PSEN1, and PSEN2 genes.

APP Mutations:
The Swedish mutation (K670N/M671L) enhances β-secretase cleavage, increasing total Aβ production approximately threefold. The London mutation (V717I) shifts γ-secretase cleavage to favor Aβ42 production. The Arctic mutation (E693G) promotes oligomer formation without affecting total production. Flemish (A692G) and Austrian (E693V) mutations cause severe cerebral amyloid angiopathy alongside AD. APP duplication mutations cause AD through true gene dosage effects, with individuals possessing three copies of APP developing pathology similar to Down syndrome.

Presenilin 1 (PSEN1) Mutations:
Over 200 pathogenic PSEN1 mutations have been identified, making this the most common cause of autosomal dominant AD. These mutations predominantly increase the Aβ42/Aβ40 ratio by altering γ-secretase activity, with minimal effects on total production. PSEN1 mutations cause the earliest onset cases, sometimes manifesting in the third or fourth decade of life.

Presenilin 2 (PSEN2) Mutations:
Fewer than 50 pathogenic PSEN2 mutations are known. These typically cause later onset than PSEN1 mutations and demonstrate reduced penetrance. Some PSEN2 variants (particularly N141I in the Volga German kindred) cause disease with near-complete penetrance.

Down Syndrome as a Genetic Model

Trisomy 21 presents a natural experiment illuminating the amyloid hypothesis[@bertram2020]. Individuals with Down syndrome possess three copies of the APP gene (located on chromosome 21), leading to lifelong Aβ overproduction. Essentially all individuals with Down syndrome develop Alzheimer-type neuropathology by age 60, providing powerful evidence for the sufficiency of APP/Aβ elevation in triggering disease. The age of onset and severity correlate with APP gene dosage, supporting the dose-response relationship predicted by the amyloid hypothesis.

Apolipoprotein E (APOE) as Risk Modifier

The APOE gene encodes the most important genetic risk factor for late-onset AD, with the ε4 allele increasing risk while ε2 provides protection[@bertram2020]. APOE influences AD risk primarily through effects on Aβ metabolism. APOE ε4 reduces Aβ clearance efficiency, promotes aggregation, and impairs lipidation of glial cells. The protein also affects synaptic function, neuroinflammation, and tau pathology independently of Aβ. Carrying one copy of ε4 approximately triples AD risk, while two copies increase risk approximately ten-fold. Biochemical studies demonstrate differential binding of APOE isoforms to Aβ, with ε4 showing stronger association and reduced clearance.

Genome-Wide Association Studies (GWAS)

Large-scale GWAS have identified numerous AD risk loci, many affecting Aβ metabolism[@huang2021]. The largest meta-analysis (Kunkle et al., 2019) identified over 30 risk loci, including CLU (Clusterin), PICALM, BIN1, ABCA7, and SORL1. Pathway analysis reveals enrichment in lipid metabolism, endocytic trafficking, and immune response genes. These findings support the importance of Aβ-related pathways in disease pathogenesis while revealing additional biological processes contributing to risk. The polygenic nature of AD suggests that accumulated small effects across multiple genes influence vulnerability.

Pathological Hallmarks and Disease Staging

Amyloid Plaque Types and Distribution

Amyloid plaques constitute a defining neuropathological feature of AD and exist in multiple morphological forms[@blennow2022]. Dense core (neuritic) plaques contain fibrillar Aβ surrounded by dystrophic neurites, tau-positive processes, and activated microglia. Diffuse plaques represent early deposits lacking the dense core and neuritic changes. Cerebral amyloid angiopathy (CAA) involves Aβ deposition in leptomeningeal and cortical blood vessels, causing hemorrhage risk and contributing to vascular dysfunction.

The spatial distribution of amyloid plaques follows a predictable progression in typical AD. Plaques initially appear in the basal temporal and orbitofrontal cortex, particularly in the precuneus and posterior cingulate. The hippocampus becomes involved relatively early, particularly in the CA1 region and subiculum. Progression continues to involve primary sensory areas while relatively sparing primary motor and visual cortices until late disease stages. The spread of pathology appears to follow specific neural networks, potentially through transsynaptic propagation.

Temporal Sequence of Pathological Changes

Neuropathological staging systems like the Braak scheme describe the progression of tau pathology but also illuminate the temporal relationship between Aβ and tau[@blennow2022]. Aβ deposition begins 10-20 years before clinical symptoms, establishing a long preclinical phase. Cerebrospinal fluid Aβ42 decreases before plaque detection by PET imaging, reflecting the shift from soluble pools to deposited amyloid. Tau pathology in the form of neurofibrillary tangles follows Aβ deposition, appearing initially in the locus coeruleus and transentorhinal cortex before spreading to limbic structures and isocortex. This temporal sequence supports the upstream role of Aβ.

Relationship Between Pathology and Clinical Symptoms

The correlation between amyloid burden and clinical phenotype is surprisingly weak. Many cognitively normal elderly individuals possess significant amyloid plaques at autopsy, while some individuals with clinical dementia show relatively modest plaque burden. This dissociation suggests that Aβ initiates a process but is not directly responsible for cognitive deficits. tau pathology correlates more strongly with cognitive impairment, and synaptic loss provides the strongest correlation with cognitive status. These observations have led to the "downstream mediator" hypothesis, which posits that Aβ triggers pathogenic processes (including tau pathology development) that directly cause cognitive decline.

Mechanistic Flowchart

The following diagram illustrates the complete causal chain from genetic and environmental triggers through to clinical Alzheimer's disease:

Flowchart Explanation

Stage 1: Genetic and Environmental Triggers
Familial AD mutations in [APP](/genes/app), [PSEN1](/genes/psen1), and [PSEN2](/genes/psen2) directly increase Aβ production. [APOE epsilon4](/genes/apoe) reduces Aβ clearance efficiency. Down syndrome provides a natural gene-dosage model. Aging impairs all clearance mechanisms.

Stage 2: Aβ Production and Aggregation
APP is cleaved by BACE1 (β-secretase) then γ-secretase to generate Aβ peptides. Aβ42 and Aβ43 are highly aggregation-prone. Primary nucleation generates oligomeric seeds. Oligomers are the primary toxic species; fibrils form plaques.

Stage 3: Aβ Toxicity and Downstream Effects
Soluble Aβ oligomers disrupt synapses, cause calcium dysregulation, promote tau hyperphosphorylation, activate microglia (neuroinflammation), damage mitochondria, and generate oxidative stress. These effects form interconnected feedback loops.

Stage 4: Tau Pathology and Neuronal Damage
Hyperphosphorylated tau assembles into neurofibrillary tangles (NFTs). Neuronal processes degenerate, synapses are lost, and axonal transport fails. Activated glia contribute to neuroinflammation, creating a vicious cycle.

Stage 5: Clinical Outcomes
Neuronal death leads to brain atrophy, neurotransmitter deficits (especially acetylcholine and glutamate), and progressive cognitive decline. Memory impairment is the earliest clinical sign, progressing to full AD dementia.

Clearance Pathways (Dotted Lines)
Multiple mechanisms clear Aβ under normal conditions: neprilysin and IDE enzymatic degradation, microglial phagocytosis, glymphatic perivascular clearance, and BBB receptor-mediated transport (LRP1). These pathways are all impaired in aging and AD.

Evidence Supporting and Challenging the Hypothesis

Neuropathological Evidence Supporting the Hypothesis

The fundamental observations supporting the amyloid hypothesis derive from neuropathological studies of AD brains[@blennow2022]. Amyloid plaques represent one of the defining neuropathological hallmarks of the disease, present in essentially all cases meeting diagnostic criteria. The spatial distribution of plaques, while not perfectly correlating with clinical symptoms, shows consistent patterns across patients. Aβ deposition precedes tangle formation both in time and in regional distribution, consistent with the cascade model. The presence of Aβ in the plaques' core, surrounded by damaged neurons and glia, suggests an upstream pathogenic role.

Genetic evidence strongly supports the amyloid hypothesis. Mutations causing familial AD directly increase Aβ production or alter the Aβ42/Aβ40 ratio[@dunn2024]. The dosage effect in Down syndrome demonstrates that increased APP gene copies cause AD. GWAS identifies numerous genes affecting Aβ metabolism as risk factors. APOE ε4, the strongest genetic risk factor, impairs Aβ clearance. The convergence of multiple independent genetic lines of evidence supports the fundamental importance of Aβ.

Biochemical and Biomarker Evidence

Cerebrospinal fluid biomarkers provide in vivo evidence for amyloid cascade dynamics[@mintun2023]. CSF Aβ42 decreases beginning in the preclinical phase, reflecting deposition in brain tissue. This decrease precedes cognitive impairment by years to decades. Phosphorylated tau increases as a marker of tau pathology and neuronal injury, appearing after Aβ changes. The Aβ42/tau ratio improves diagnostic accuracy and predicts progression from MCI to AD. PET imaging with amyloid ligands allows visualization of plaque burden in living subjects, demonstrating the preclinical accumulation of amyloid[@mucke2010].

Clinical Trial Outcomes: Anti-Amyloid Therapies

Despite compelling preclinical data, anti-amyloid clinical trials have yielded mixed and often disappointing results[@bateman2022][@reiman2021]. The failures have prompted fundamental reconsideration of the amyloid hypothesis while also revealing important insights about therapeutic timing and patient selection.

Immunotherapy Outcomes:
Solanezumab, targeting soluble Aβ, failed to meet primary endpoints in the EXPEDITION trials. Crenezumab, designed to target oligomers, failed in the GRADUATE trials despite theoretical advantages. Aducanumab showed dose-dependent plaque reduction but received controversial FDA approval based on amyloid removal rather than clinical benefit, later withdrawn voluntarily. Lecanemab demonstrated 27% slowing of clinical decline in CLARITY-AD, meeting its primary endpoint. Donanemab showed 35% slowing in TRAILBLAZER-ALZ 2. Both antibodies received FDA approval, representing the first disease-modifying therapies for AD.

Secretase Inhibitor Failures:
BACE inhibitors yielded particularly negative results despite strong preclinical rationale[@salloway2022]. Verubecestat worsened cognition in the CTEP trial, leading to early termination. Atabecestat showed cognitive worsening in the EARLY trial. These results raised concerns that BACE inhibition, while reducing Aβ, produced off-target effects that harmed cognition. Subsequent research showed BACE has physiological substrates essential for synaptic function, explaining the adverse cognitive effects.

Alternative Pathogenic Models

The failures of anti-amyloid therapies have prompted development of alternative models[@hardy2022]. The multiple hit hypothesis proposes that Aβ initiates but other factors, including tau pathology, neuroinflammation, and vascular dysfunction, determine disease progression. The tau-centric model suggests tau pathology as the primary driver of neurodegeneration, with Aβ serving as an accelerator rather than cause. The inflammatory model emphasizes microglial activation and chronic neuroinflammation as upstream events. These models are not mutually exclusive and may reflect the complexity of sporadic AD.

Therapeutic Strategies Targeting Amyloid

Monoclonal Antibodies Against Aβ

Anti-amyloid monoclonal antibodies represent the leading therapeutic approach and the only FDA-approved disease-modifying treatments[@bateman2022][@reiman2021]. Lecanemab (Leqembi) received accelerated approval in 2023 and full approval in 2024 based on CLARITY-AD trial results showing 27% slowing of clinical decline. The antibody binds to soluble Aβ protofibrils with high affinity, providing preferential clearance of toxic oligomeric species. Donanemab (Kisunla) received FDA approval in 2024 based on TRAILBLAZER-ALZ 2 results demonstrating 35% slowing of decline in early AD patients. Both treatments require amyloid PET confirmation and regular MRI monitoring for amyloid-related imaging abnormalities (ARIA).

Amyloid-Related Imaging Abnormalities (ARIA):
ARIA represents an expected class effect of anti-amyloid antibodies. ARIA-E involves fluid-attenuated inversion recovery (FLAIR) hyperintensities reflecting edema or sulcal effusions. ARIA-H represents microhemorrhages or cortical siderosis. Risk factors include high amyloid burden, APOE ε4 carrier status, and concurrent anticoagulation. Management includes dose initiation and titration, baseline and serial MRI monitoring, and clinical vigilance for symptoms.

Immunotherapy and Vaccination Approaches

Active immunization strategies aim to induce endogenous anti-Aβ antibody production. ACI-35 represents a liposome-based vaccine targeting phosphorylated tau. ABvac3 employs a multi-epitope Aβ vaccine. Several vaccines have demonstrated safety but failed to achieve clinical efficacy in Phase 3 trials. The challenge involves generating appropriate antibody responses without excessive T-cell activation or autoimmunity.

Secretase Modulation

γ-Secretase modulators (GSMs) aim to shift catalytic cleavage to favor shorter, less aggregation-prone Aβ species[@egan2018]. Unlike inhibitors (which block all γ-secretase activity), modulators alter the cleavage position without complete enzyme inhibition. This approach may reduce side effects related to complete Notch pathway disruption. Several GSMs have advanced to clinical testing, though none have yet achieved FDA approval.

BACE inhibitors were extensively investigated but failed due to mechanism-based cognitive adverse effects[@salloway2022]. The recognition that BACE has physiological substrates essential for synaptic function limits the feasibility of complete BACE inhibition. Partial inhibition strategies and substrate-specific approaches remain under investigation.

Alternative Approaches

α-Secretase activators would promote the non-amyloidogenic pathway, theoretically reducing Aβ production while increasing production of neuroprotective sAPPα. No such agents have yet achieved clinical success. Anti-aggregation compounds aim to prevent oligomer formation or promote clearance of existing oligomers. Approaches include peptide inhibitors, small molecules, and antibody fragments. Albumin-based approaches explored portable chaperone functions and Aβ sequestration from brain.

Cross-Links to Related Topics

Understanding the amyloid cascade integrates with numerous NeuroWiki topics:

• [Alzheimer's Disease](/diseases/alzheimers-disease) — The primary disease context
• [Amyloid Precursor Protein (APP) — Gene](/genes/app) — The source protein
• [Amyloid Precursor Protein (APP) — Protein](/proteins/app) — The protein product
• [Amyloid-Beta Peptides](/proteins/amyloid-beta-peptide) — The central protagonist
• [Tau Pathology in Alzheimer's Disease](/mechanisms/tau-pathology-alzheimers) — The downstream partner
• [APOE Gene](/genes/apoe) — Major genetic risk factor
• [BACE1 Gene](/genes/bace1) — The beta-secretase
• [Presenilin 1 (PSEN1) Gene](/genes/psen1) — Catalytic component
• [Presenilin 2 (PSEN2) Gene](/genes/psen2) — Alternative catalytic component
• [Cerebrospinal Fluid Biomarkers](/mechanisms/csf-biomarkers-alzheimers) — Diagnostic markers
• [Amyloid PET Imaging](/technologies/amyloid-pet-imaging) — Diagnostic imaging

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Precursor Protein (APP) — Gene](/genes/app)
• [Amyloid Precursor Protein (APP) — Protein](/proteins/app)
• [Amyloid-Beta Peptides](/proteins/amyloid-beta-peptide)
• [Tau Pathology in Alzheimer's Disease](/mechanisms/tau-pathology-alzheimers)
• [APOE Gene](/genes/apoe)
• [BACE1 Gene](/genes/bace1)
• [Presenilin 1 (PSEN1) Gene](/genes/psen1)
• [Presenilin 2 (PSEN2) Gene](/genes/psen2)
• [Cerebrospinal Fluid Biomarkers](/mechanisms/csf-biomarkers-alzheimers)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Amyloid Cascade Pathway discovered through SciDEX knowledge graph analysis: